Format

Send to:

Choose Destination
See comment in PubMed Commons below
Dtsch Arztebl Int. 2008 Apr;105(14):255-62. doi: 10.3238/arztebl.2008.0255. Epub 2008 Apr 4.

Pancreatic cancer--low survival rates.

Author information

  • 1Abteilung für Allgemein- und Viszeralchirurgie, Klinikum der Universität Ulm, Steinhövelstrasse 9, Ulm, Germany. hans.beger@medizin.uni-ulm.de

Abstract

INTRODUCTION:

Cancers of the pancreas are identified in 11 800 to 13 500 patients each year in Germany. Epidemiological studies prove smoking and chronic alcohol consumption as causes of about 30% of pancreatic cancers.

METHODS:

Selective literature review.

RESULTS:

Only patients within TNM stage I and II have after oncologic tumor extirpation a chance for long term survival. Controlled prospective clinical trials demonstrated adjuvant chemotherapy yielding an additional significant survival benefit. The 3- and 5-year-survival after R0-resection and adjuvant chemotherapy are about 30% and below 15% respectively. Using the criteria of observed 5-year-survival less than 2% of all pancreatic cancer patients are alive. After R0-resection the median survival time is between 17 and 28 months, after R1/2-resection between 8 and 22 months.

DISCUSSION:

Pancreatic cancer is even today for more than 95% of the patients incurable. Strategies to prevent pancreatic cancer are intended to stop smoking and chronic alcohol consumption and early surgical extirpation of cystic neoplastic lesions. For patients with established pancreatic cancer risk a follow-up protocol is discussed.

KEYWORDS:

R0-resection; adjuvant chemotherapy; early cancer dissemination into nerves; lymph tissue and blood circulation; pancreatic cancer; systemic disease

Comment in

PMID:
19629206
[PubMed]
PMCID:
PMC2696777
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Deutsches Aerzteblatt International Icon for PubMed Central
    Loading ...
    Write to the Help Desk